ClinicalTrials.gg
Not yet recruitingNCT06072326ASPIRE-1Updated Oct 20, 2026

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

A Phase 2 interventional study of Dapagliflozin (Forxiga®) and SC0062 strength 10mg in Type 1 Diabetes Mellitus With Diabetic Nephropathy, sponsored by University Medical Center Groningen. Not yet recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026No longer in NetherlandsStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetic Nephropathies with a site in Denmark — 6 open to participants now, 6 under way, none of them phase 3. Diabetic Nephropathies · Denmark.

Planned enrollment
28th of 36
36 · median 61
Started
2027
the only one that year
Phase 2
14 of 42
3 open now
Registered
38th of 42
by date
Lead sponsor
2 of 42
University Medical Center Groningen

Among the 42 studies in Diabetic Nephropathies with a site in Denmark, this one is the 28th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2027, is one of 14 in phase 2, and was the 38th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

6 of the 42 studies in Diabetic Nephropathies with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetic Nephropathies with a site in Denmark, or all of them as a file.
02

Study summary

The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.

Read the detailed description

A phase 2, multicenter, randomized, open-label, cross-over trial will be conducted in male or female individuals (N=36) diagnosed with type 1 diabetes at least 6 months prior to informed consent aged between 18 and 65 years, Body Mass Index (BMI) ≥ 21 kg/m2, urinary albumin: creatinine ratio ≥ 50 mg/g and \< 3000 mg/g, eGFR > 30 and \<90 mL/min/1.73 m2 and HbA1c > 6.5 and \<10.5%. Patients have to be on stable RAAS inhibition for at least 4 weeks prior to screening.

The study will consist of a screening visit, a 4-week run-in phase. After the run-in phase, the participant will be randomized to treatment of SC0062, dapagliflozin, or their combination in random order. The duration of each treatment period is 4 weeks with study visits scheduled at 2 and 4 weeks in each treatment period. At the end of each treatment period patients proceed to a 4 weeks wash-out phase to study off drug effects. The total duration of the study for each participant after randomization is thus 24 weeks

Interventions SC0062 10mg twice daily (20mg/day); dapagliflozin 5mg once daily; combination of SC0062 10mg twice daily and dapagliflozin 5mg once daily.

03

Conditions studied

  • Type 1 Diabetes Mellitus With Diabetic Nephropathy

Keywords

  • Diabetic kidney disease
  • sodium glucose co-transporter 2 inhibitors
  • endothelin receptor antagonists
  • Type 1 Diabetes
  • combination therapy
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to sign
  • Male or female individuals diagnosed with type 1 diabetes at least 6 months prior to informed consent
  • must have a negative pregnancy test at screening and must not be lactating.
  • Male individuals must use highly effective method of for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, or be able to provide proof of vasectomy.
  • Female individuals must use highly effective method of contraception for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, provide proof of hysterectomy or sterilization, or be deemed menopausal based on a FSH-test.
  • Age ≥18 and \<65years, at the time of signing consent.
  • ≥ 21 kg/m2
  • Urinary albumin:creatinine ratio ≥ 50 mg/g and \<3000 mg/g
  • ≥30 and \<90 ml/min/1.73m2
  • Stable RAAS inhibition medication for at least 4 weeks prior to screening
  • ≥6.5 and \<10.5%.
  • Based on the Investigator's judgment participant must have a good understanding of his/her disease and how to manage it, and be willing and capable of performing the following study assessments (assessed before randomization):

    • patient-led management and adjustment of insulin therapy
    • reliable approach to insulin dose adjustment for meals, such as carbohydrate counting
    • reliable and regular home-based blood glucose monitoring
    • established "sick day" management regimen

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 2 diabetes, or other types of diabetes (e.g. LADA).
  • Treatment with an anti-hyperglycaemic agent (e.g., metformin, alpha-glucosidase inhibitors, pramlintide, glucagon-like peptide receptor agonist, etc.) within 3 months.
  • Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemia-related treatment by an emergency physician or paramedic within 3 months.
  • Hypoglycaemia unawareness based on Investigator judgement or frequent episodes of unexplained hypoglycaemia (2 or more unexplained episodes within 3 months).
  • Occurrence of diabetic ketoacidosis within 6 months prior to study enrolment.
  • Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or within 6 months.
  • Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g., patients, patients who might be at higher risk of developing urinary, genital or mycotic infections, patients with chronic viral infections, etc.).
  • Treatment with an SGLT2i within 30 days of Visit 1.
  • NT-proBNP > 600 pg/mL
  • \< 90 g/L
  • Diagnosis of severe edema (per investigator judgment) within 3 months of screening
  • Diagnosis of heart failure (NYHC stage III or IV).
  • Strong inducers or strong CYP3A4 inhibitors
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Treatment order 1

    Subjects will start with 4 weeks of SC0062 in treatment period 1. In period 2 subjects will receive dapagliflozin. In period 3 subjects will receive a combination of SC0062 and dapagliflozin. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

  • Experimental
    Treatment order 2

    Subjects will start with 4 weeks of SC0062 in treatment period 1. In period 2 subjects will receive a combination of SC0062 and dapagliflozin. In period 3 subjects will receive dapagliflozin. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

  • Experimental
    Treatment order 3

    Subjects will start with 4 weeks of dapagliflozin in treatment period 1. In period 2 subjects will receive a combination of SC0062 and dapagliflozin. In period 3 subjects will receive SC0062. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

  • Experimental
    Treatment order 4

    Subjects will start with 4 weeks of dapagliflozin in treatment period 1. In period 2 subjects will receive SC0062. In period 3 subjects will receive a combination of SC0062 and dapagliflozin. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

  • Experimental
    Treatment order 5

    Subjects will start with 4 weeks of a combination of SC0062 and dapagliflozin in period 1. In period 2 subjects will receive SC0062. In period 3 subjects will receive dapagliflozin. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

  • Experimental
    Treatment order 6

    Subjects will start with 4 weeks of a combination of SC0062 and dapagliflozin in period 1. In period 2 subjects will receive dapagliflozin. In period 3 subjects will receive SC0062. Between treatment periods there is a 4-week wash-out.

    Drug: Dapagliflozin (Forxiga®) · Drug: SC0062 strength 10mg · Drug: SC0062 and dapagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Urine Albumin-Creatinine Ratio (UACR)

    Primary: change from baseline in Urine Albumin-Creatinine Ratio (UACR) when treated with SC0062 alone versus combination of dapagliflozin and SC0062.

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

Secondary outcomes

  1. Change from baseline in eGFR

    Estimated Glomerular Filtration Rate (GFR) - creatinine

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  2. Change in biomarkers of fluid retention

    Change from baseline biomarkers of fluid retention (Body Weight)

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  3. Change in biomarkers of fluid retention

    Change from baseline biomarkers of fluid retention (hemoglobin)

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  4. Change in biomarkers of fluid retention

    Change from baseline biomarkers of fluid retention (N-terminal prohormone of Brain Natriuretic Peptide (NT-proBNP))

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  5. Change from baseline Extracellular Volume (ECV)

    Extracellular volume (ECV) using iohexol clearance techniques and bioimpedance spectroscopy.

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  6. Change from baseline blood pressure

    Change in blood pressure as measure in mmHg

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

  7. Safety of dapagliflozin, SC0062, and combination of dapagliflozin and SC0062

    Body weight, vital signs, physical examination findings, ECG, and clinical laboratory parameters AEs, Serious AEs, DKA, and drug-induced liver injury.

    Time frame: From randomization to end of study (V10) up to approximately 24 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 24 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jan 2026 → Jan 2027, primary completion Dec 2027 → Jan 2029 and completion Dec 2028 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 10, 2023
StartEst.
Jan 2027was Jan 2026
Primary completionEst.
Jan 2029was Dec 2027
CompletionEst.
Jan 2030was Dec 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed; no longer in Netherlands
Show 2 removed
  • Amsterdam University Academic Center · Amsterdam, Netherlands
  • University Medical Center Groningen · Groningen, Netherlands
Oct 20, 2026
Start date
Jan 2026→Jan 2027
Oct 20, 2026
Primary completion
Dec 2027→Jan 2029
Oct 20, 2026
Study completion
Dec 2028→Jan 2030
Oct 20, 2026
Eligibility
Maximum age 65 Years→64 Years; 1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedStrong CYP3A4 inducers or strong CYP3A4 inhibitors
Oct 20, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange from baseline in Urine Albumin-Creatinine Ratio (UACR)4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
Oct 20, 2026
Secondary outcomes
2 edited, 5 time frame changed, 3 description edited
What changed in the outcomes
  • EditedChange from baseline in mGFReGFRTime frame: 4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • ChangedBefore Change in biomarkers of fluid retentionNow Safety of dapagliflozin, SC0062, and combination of dapagliflozin and SC0062Time frame: 4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • Time frameChange in biomarkers of fluid retention4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • Time frameChange in biomarkers of fluid retention#24 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • Time frameChange in biomarkers of fluid retention#34 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • Time frameChange from baseline Extracellular Volume (ECV)4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • Time frameChange from baseline blood pressure4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
  • DescriptionChange in biomarkers of fluid retention: how it is measured was reworded
  • DescriptionChange in biomarkers of fluid retention#2: how it is measured was reworded
  • DescriptionChange in biomarkers of fluid retention#3: how it is measured was reworded
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites removed; no longer in Netherlands
    Show 2 removed
    • Amsterdam University Academic Center · Amsterdam, Netherlands
    • University Medical Center Groningen · Groningen, Netherlands
    Start date Jan 2026→Jan 2027
    Primary completion Dec 2027→Jan 2029
    Study completion Dec 2028→Jan 2030
    Eligibility Maximum age 65 Years→64 Years; 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedStrong CYP3A4 inducers or strong CYP3A4 inhibitors
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange from baseline in Urine Albumin-Creatinine Ratio (UACR)4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    Secondary outcomes 2 edited, 5 time frame changed, 3 description edited
    What changed in the outcomes
    • EditedChange from baseline in mGFReGFRTime frame: 4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • ChangedBefore Change in biomarkers of fluid retentionNow Safety of dapagliflozin, SC0062, and combination of dapagliflozin and SC0062Time frame: 4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • Time frameChange in biomarkers of fluid retention4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • Time frameChange in biomarkers of fluid retention#24 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • Time frameChange in biomarkers of fluid retention#34 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • Time frameChange from baseline Extracellular Volume (ECV)4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • Time frameChange from baseline blood pressure4 weeks → From randomization to end of study (V10) up to approximately 24 weeks
    • DescriptionChange in biomarkers of fluid retention: how it is measured was reworded
    • DescriptionChange in biomarkers of fluid retention#2: how it is measured was reworded
    • DescriptionChange in biomarkers of fluid retention#3: how it is measured was reworded
    + 4 other changes: identifiers, verification date, oversight details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072326
Collaborators
Juvenile Diabetes Research Foundation, Biocity Biopharmaceutics Co., Ltd.
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Hiddo J Lambers Heerspink, Phd, PharmD
Contact
h.j.lambers.heerspink@umcg.nl
+31-50-3617859
Hiddo J Lambers Heerspink, PhD, PharmD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diosuxentan · Dapagliflozin

Start the discussion